The BioPsych team has access to the World’s biggest brain collection. This collection of post-mortem brain tissue will be used to identify biomarkers for diseases such as schizophrenia, bipolar disorder and depression. “These brains are rather unique because they were collected from 1945 to 1982. Therefore, these patients have never been subjected to any kind of modern medicine.” says Betina Elfving, who is head of the BioPsych project. The project aims not only to identify biomarkers but also develop radio-tracers for in vivo imaging.
2022.06.20 | SUSANNE TRILLINGSGAARD VENØ
The national experience sharing network for NGS entusiasts, meet in Aarhus to discuss the potential in diagnostics and therapeutics
In recent years NGS has transitioned from research to clinical use and more hospitals have central NGS units that serve as a platform for NGS to be part of the clinical routine. With the emergence of RNA sequencing, many novel types of RNA have been discovered using exploratory high-throughput sequencing, with the potential to act as a diagnostic marker or therapeutic targets. What are the possibilities with next-generation sequencing (NGS)? The event indeed brought companies and researchers together to inspire and broadening the view of many of the kinds of NGS technology potentials.
Thanks to invited speakers David Nelles, Jakob Hedegaard, Jørgen Kjems, Ole Halfdan Larsen, and Gitte Pedersen for some inspiring and thoughtful presentations.
The event was organised by omiics CEO, Susanne Trillingsgaard Venø, Signe Ulrik Holm, and Jane Nøhr from Danish Life Science Cluster.
2022.06.14 | SUSANNE TRILLINGSGAARD VENØ
CTO of omiics, Morten Venø, has been invited to give a lecture at EMBL on circRNA bioinformatics analysis of ONT long-read data
Circular RNA (circRNA) is a class of covalently joined non-coding RNAs with functional roles in a wide variety of cellular processes. Their composition shows extensive overlap with exons found in linear mRNAs making it difficult to delineate their composition using short-read RNA sequencing, particularly for long and multi-exonic circRNAs.
In a collaboration with the Jørgen Kjems research at Aarhus University, Morten Venø has been partner in developing a novel approach for targeted long-read sequencing of a panel of circRNAs (circPanel-LRS), eliminating the need for prior circRNA enrichment. Here, Morten Venø developed the bioinformatic pipeline udes to analyse the panel data produced from the method, a story he will share at his lecture at the EMBL
2022.04.02 | SUSANNE TRILLINGSGAARD VENØ
Based on customer requests, omiics now offer optimized mim-tRNA sequencing as a service
Transfer RNAs (tRNAs) are short, abundant transcripts needed for translating messenger RNA into protein. As such, the composition of cellular tRNA pools impact proteome dynamics and integrity. tRNA expression is dynamically regulated in different tissues and during development, and defective tRNA biogenesis is linked to neurological disorders and cancer.
Classic next generation sequencing has been challenged in measuring cellular tRNA abundance, due to pervasive blocks of cDNA synthesis at modified nucleosides and the extensive similarity among tRNA genes. Mim-tRNA sequencing overcome these issues and uncover a dramatic heterogenety of tRNA isodecoder pools between human cell lines and also showed there to be a interdependence of modifications within an individual tRNA transcript
2022.02.07 | SUSANNE TRILLINGSGAARD VENØ
Meet omiics CTO Morten Venø at the conference in Copenhagen 1.-3. dec 2021
At the conference in Copenhagen, omiics founder and CTO Morten Venø presented a customer project on RNA biomarkers in cell-free bioliquids; specifically detection of miRNA, circRNA and tRNA fragments in bile.
2021.12.01 | SUSANNE TRILLINGSGAARD VENØ
Interview with omiics CEO Susanne Trillingsgaard Venø about her role in a new national experience network
Read about the the ideas and efforts behind establishing a new national network across NGS entusiasts from academia, hospitals and industry in Denmark
2021.11.16 | SUSANNE TRILLINGSGAARD VENØ
omiics publication in Nature communication
In 2021, a method paper was published in Nature Communication on the usage of long-read sequencing technology. The method circumvents previous analyse limitation of circRNA, as the use of short-read Illumina sequencing only allowed detection of circRNAs, but did not support full-length characterization. In this work, omiics developed the bioinformatic pipeline for both the initial analysis and the circRNA panel.
2021.08.30 | SUSANNE TRILLINGSGAARD VENØ
New Website for PRIME
The ERC FET OPEN Consortium - PRIME has a new webpage
In 2020, omiics partnered on a successful ERC FET Open Grant, PRIME. The project has a new website! You can now read more about how omiics will provide expertise in low input RNA sequencing and bioinformatics analysis for this innovative and exciting project!
2021.06.29 | SUSANNE TRILLINGSGAARD VENØ
omiics CEO Susanne Trillingsgaard Venø featured in article on mentorship in start-ups
Read about the journey of our company and our leadership on this feature piece authored by Susanne herself.
2021.06.21 | SUSANNE TRILLINGSGAARD VENØ
omiics publication featured in Aarhus University news
Epilepsy is one of the most common neurological diseases, and seizures can be debilitating. Unfortunately, treatments to prevent these seizures are lacking. Jørgen Kjems from iNANO and the Department of Molecular Biology at Aarhus University and the AU spinout company, OMIICS, are partners in a new consortium, PRIME, that will seek to develop biological nano-implants - based on naturally occurring signaling pathways - that can help patients with epilepsy.
2021.03.10 | ANNE FÆRCH NIELSEN
omiics publication featured in Aarhus University news
A new paper from Jørgen Kjems' group at iNANO and MBG describes how expression of non-coding RNA changes during epileptic seizures in rodents. The authors found that inhibiting a specific set of microRNAs (miRNAs) by antisense technology reduced seizure frequency in a mouse model, suggesting that these RNA molecules could serve as possible targets for future epilepsy therapy.
2020.06.25 | ANNE FÆRCH NIELSEN
NGS service provider with a focus on customer needs. We deliver flexible solutions to your specific demands.
Contact us for a non-binding discussion about your next project.
(+45) 28 72 71 07
CVR: 39 73 23 43